Background: Aberrant kallikrein activity is observed in a number of inflammatory dermatoses. Up-regulation of kallikrein-5 (KLK5) activity leads to uncontrolled skin desquamation and cleavage of proteinase-activated receptor-2 (PAR2), causing the release of pro-inflammatory cytokines and disruption of epidermal barrier function. This study aimed to identify KLK5-specific small molecule inhibitors which can serve as the foundation of a novel therapeutic for inflammatory skin disorders. Methods: Five chemical libraries (13,569 compounds total) were screened against recombinant KLK5 using a fluorogenic enzymatic assay. Secondary validation was performed on the top 22 primary hits. All hits were docked in the KLK5 crystal structure to rationalize their potential interactions with the protein.
Introduction
Human tissue kallikreins (KLKs) are a family of 15 secreted serine proteases involved in an array of physiological processes in the human body [1] . Specifically, several KLKs are located in the skin where they function in an enzymatic cascade to maintain proper epidermal barrier function [2, 3] . KLKs play a major role in skin lipid permeability via their cleavage of pro-fillagrin, resulting in the incorporation of its monomers into the lipid envelope of the epidermis [4] . KLKs also activate other epidermal proteases responsible for further proteolysis of fillagrin into natural moisturizing factors (NMF) that assist in water retention [5] . Additionally, KLKs are involved in antimicrobial defense and innate immune response by processing proteins such as cathelicidin, into their active antimicrobial peptides [6] . The most well-characterized role of KLKs is skin desquamation, where they mediate skin renewal through the degradation of corneodesmosomes in the stratum corneum [7, 8] . Proper regulation of KLK activity is maintained by the acidic surface mantle of the skin and the presence of protease inhibitors in the epidermis, such as lymphoepithelial Kazal-type 5 serine protease inhibitor (LEKTI) [9, 10] .
Uncontrolled KLK activity has been observed in many skin disorders that are characterized by compromised skin barrier function and inflammation [2, 11] . An elevation in KLK activity is associated with inflammatory dermatoses such as, peeling skin syndrome, psoriasis, acne rosacea and atopic dermatitis (AD) [12] [13] [14] [15] . KLKs also have the ability to activate keratinocyte-cell surface proteinase-activated receptors (PARs) resulting in NFκB-directed cytokine bursts and subsequent inflammation and/or thymic stromal lymphopoietin (TSLP)-mediated allergy [16, 17] .
Compelling evidence for the role of excess KLK activity in the pathogenesis of inflammatory skin disorders is illustrated in the disease, Netherton syndrome (NS). NS is the result of mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene which encodes LEKTI [18] . Reduced levels of functional LEKTI result in the uncontrolled degradation of corneodesmosomes by kallikrein-5 (KLK5) and a severely dysfunctional epidermis [19, 20] . Moreover, KLK5 will also activate proteinase-activated receptor 2 (PAR2) thereby triggering a pro-inflammatory pathway resulting in a clinical phenotype characterized by severe erythroderma [20] [21] [22] .
Inhibitors of skin KLKs are attractive targets for pharmaceutical development of cosmetic agents to improve skin barrier function and for targeted-therapies of inflammatory dermatoses [23] . Despite being a promising target, there remains an urgent need for the discovery of novel KLK inhibitors to facilitate the development of topical drugs for the treatment of these skin disorders. The objective of this work is to employ high-throughput screening to identify novel KLK5 inhibitors for use in the prevention of unregulated KLK5 activity in the skin.
Materials and methods

Recombinant protein expression and purification
Recombinant active KLK5 was cloned, expressed and purified in a similar manner as published in [24] . Briefly, a polymerase chain reaction (PCR)-amplified DNA fragment encoding mature human KLK5 with the pro-peptide absent, was cloned into the pPIC9 expression vector. This construct was then linearized and transformed into KM71 Pichia pastoris (P. pastoris) via electroporation. A stable KM71 transformant was grown in BMGY media for 2 days, centrifuged and then the cell pellet was resuspended in BMMY media (A 600 = 10). KLK5 expression was induced with 1% methanol for 5 days at 30 °C in a shaking incubator (250 RPM). The recombinant protein was purified from culture supernatant by ultrafiltration, serial dialysis and centrifugation procedures, ending with cation exchange chromatography. One liter of culture containing secreted mature KLK5 was centrifuged and the supernatant was concentrated 10-fold by positive pressure ultracentrifugation in an Amicon™ stirring chamber (Millipore Corporation, Bedford, MA, USA) with a 10-kDa cutoff regenerated cellulose membrane. The active protein was then purified using an optimized and automated ÄKTA fast protein liquid chromatography (FPLC) method on a pre-equilibrated 5 mL cation exchange HiTrap high performance Sepharose HP-SP column (GE Healthcare). The purification running buffer for KLK5 was 50 mM sodium acetate (pH 5.3) with the elution buffer comprised of the running buffer with an additional 1 M sodium chloride. KLK5 was eluted in 4 mL fractions using a linear/stepwise gradient and the eluted fractions were tested for KLK5 expression using a KLK5-specific in-house developed sandwich-style ELISA [25] , silver-stained SDS-PAGE (PlusOne Silver Staining Kit, protein, GE Healthcare) (Supplementary Material, Figure 1 ) and enzymatic activity assays (described below). The yield of purified active KLK obtained per 1 L of culture supernatants was in the range of 0.8-1.5 mg, as determined by ELISA and BCA total protein assays. Fractions containing the pure active protease were pooled, concentrated, aliquoted and stored at −80 °C. All expression and purification was conducted in the research laboratory in accordance with the health and safety protocols outlined by the institute. Obtainment of Research Board Approval was not applicable, as human subjects were not involved in this study.
Primary screening methodology
Prior to the screen, KLK5 kinetic profiling was performed for determination of K m , K cat and V max (Supplementary Material, Figure 2 ). Additionally, enzymatic stability, resistance to DMSO and Z-factor were also optimized to ensure proper performance in a high-throughput capacity. The primary screen was performed in 384-well plates (Corning, Corning, NY, USA) in duplicate using a fully automated Beckman/Coulter Sagian core system (Beckman Coulter Inc., Fullerton, CA, USA). Twenty micromolar of each compound were roboticallydispensed in duplicate wells of a 384-well plate followed by 0.2 mM of the fluorogenic 7-amino-4-methylcoumarin (AMC) peptide (valineproline-arginine; VPR) substrate (Bachem Bioscience, King of Prussia, PA, USA). Twenty nanomolar of active recombinant KLK5 were then added to each well and the fluorescence was measured every minute for the first 20 min on an Envision plate reader (Perkin Elmer, Waltham, MA, USA). Positive (enzyme without any compounds) and negative (compound without enzyme) controls were randomly scattered in the assay plates to avoid position biases (e.g. edge effects) and to be compared to fluorescence readings obtained in test wells. Primary hits were selected based on whether the compound displayed more than 50% inhibition of KLK5 activity.
Secondary screening methodology
Secondary screening was carried out in a similar fluorescence assay protocol to determine IC 50 values. Compounds were tested in a doseresponse manner using 11 serial dilutions ranging from 100 μM to 0.001 μM. Assays were performed in duplicates. The potential of these compounds to interfere with the assay was also assessed by co-incubating increasing doses of each inhibitor compound with free fluorescent AMC, to remove false positives.
Data analysis and IC 50 determination
In Microsoft Excel, the fluorescence values obtained from the AMC substrate alone (enzyme-free background control) were subtracted from the raw values. The reaction rate was then calculated by measuring the slope in fluorescence units/min. Slopes were then used to calculate the IC 50 and K i values using SigmaPlot 8.0 (SPSS Inc., Chicago, IL, USA) to perform a least squares logistic (sigmoidal) regression curve fit for dose-response inhibition (log[inhibitor] versus response-variable slope formula). Compound-specific IC 50 values were determined by sigmoidal regression to the following fourparameter equation:
as previously described [26] . To eliminate false-positive hits (e.g. non-specific inhibition, compound interference) all possible controls were added per compound (substrate alone, inhibitor alone, substrate plus inhibitor and substrate plus enzyme).
Fluorogenic AMC substrate enzymatic assay for inhibitor specificity
All recombinant KLK proteins were produced as outlined previously [24] . For the AMC-substrate enzymatic assays, the corresponding AMC peptide (the trypsin-like proteases KLK5, KLK6 (0.015 μM), KLK8 (0.0012 μM), KLK13 (0.044 μM) and KLK14 (0.0008 μM) were assayed using the peptide VPR-AMC and the chymotryptic-like protease KLK7 (0.133 μM) was assayed using the peptide LLVY-AMC) was diluted in the appropriate enzyme activity buffer (all KLKs aside from KLK6 were tested in a reaction buffer composed of 20 mM Tris, 150 mM sodium chloride, 0.01% Tween 20, pH 8 and for KLK6, reaction buffer was composed of 20 mM Tris, 100 mM sodium chloride, 0.2% bovine serum albumin, pH 7.3) to a final concentration of 0.5 mM. Each skin kallikrein was incubated with varying concentrations of the inhibitor compound (100 μM, 33 μM, 11.1 μM, 3.7 μM) or mock (DMSO)-treated as a control for 15 min at 37 °C, shaking. The diluted AMC peptide was added to its corresponding enzyme and free AMC fluorescence was measured immediately on the Wallac 1420 Victor fluorometer (PerkinElmer Life Science) with excitation and emission filters set at 380 and 480 nm, respectively, at 1 min intervals for 30 min at 37 °C. Enzyme-free reactions were included to be used as background controls. Experiments were performed in duplicate. The percent inhibition was calculated using the formula:
(Sample RFU Minimum RFU) Percent Inhibition 1 100 (Maximum RFU Minimum RFU)
where, RFU corresponds to the 'relative fluorescence units'. The maximum RFU value corresponded to enzyme-only control and minimum RFU corresponded to substrate-only control. IC 50 value determination was carried out as mentioned.
Results
To identify novel specific inhibitors of active KLK5, a high-throughput screen was conducted. A total of 13,569 compounds from five chemical libraries (Table 1) were tested in duplicate and compounds which resulted in more than a 50% inhibition in the activity of KLK5 (as measured 20 min after addition of the inhibitors) were defined as primary "hits". If their RFU values were not within 85%-115% of the RFU of the positive controls they were removed to exclude compounds which caused interference with the assay (Figure 1 ). Twenty-two compounds were identified as potential KLK5 inhibitors. These 22 compounds were subjected to a validation screen to confirm the initial results. Each compound was added to a single row of a 384-well plate in 11 serial dilutions in duplicate, from 0.0001 μM to 100 μM. The validation screen yielded one compound from the ChemBridge library that was a KLK5 inhibitor (IC 50 : 17.3 μM) (Figure 2A ). The K i was calculated to be 6.4 μM (Supplementary Material, Figure 2 ). This compound is called Brazilin [(6aS,11bR)-7,11b-dihydro-6H-indeno[2,1-c] chromene-3,6a,9,10-tetrol] ( Figure 2B ).
To determine the selectivity of the lead compound against the other skin kallikreins (KLK6, KLK7, KLK8, KLK13 and KLK14) a fluorogenic AMC assay was used to determine percent inhibition of each enzyme and calculate the corresponding IC 50 values ( Table 2 ). IC 50 values were calculated using GraphPad Prism's logistic regression curve fit for dose response. For KLK5 the IC 50 value was 20.3 μM, which is consistent with what was found during the screening process ( Figure 2A and Table 2 ). KLK14 was also found to be susceptible to inhibition by Brazilin with a calculated IC 50 value of 14.6 μM ( Table 2 ). Brazilin was docked with Glide (Schrodinger, Inc.) using SP scoring function in the crystal structure of KLK5 (PDB code 2PSX) with the Leu-containing peptide (leupeptin), resolved at 2.3 Å resolution [27, 28] . The docking hypothesis suggests that the phenolic moiety of Brazilin binds in the S1-pocket of KLK5 and forms a H-bond with S195 side chain (Figure 3 ). The whole molecule has a "clip"-like shape and presumably one side of it clips in the S1-pocket, while the other site forms a H-bond towards the S1'-pocket, forming favorable van der Waals contact with the protein. The binding mode is stabilized by an additional H-bond between the aliphatic alcohol of Brazilin and side chain of Q192.
Discussion
Inflammatory skin diseases affect millions of people worldwide and although mild-to-moderate disease is managed well by traditional therapeutics, this is often not the case in patients with severe disease phenotype and excessive epidermal barrier breakdown [29, 30] . As such, KLKs have become attractive therapeutic targets, with a number of groups investigating potential inhibitors of these important skin enzyme [31] [32] [33] .
The KLK5 inhibitor compound identified from this screen is called Brazilin and is an extract from the plant Caesalpinia sappan, commonly known as Brazil or Using a fluorogenic enzymatic assay, the percent of activity of KLK5 following incubation with each inhibitor was calculated and the two replicates were plotted against one another. Blue dots represent those compounds that are relatively strong inhibitors of KLK5, while all other colored dots represent compounds which did not have a significant effect on KLK5 activity. sappan wood. Brazilin is the major compound naturally occurring in the heartwood of C. sappan and has been used as a red dye [34] . It is a lignan compound which refers to a large class of polyphenols found in plants and one of the major classes of phytoestrogens (estrogen-like chemicals). Many lignans are under research for their potential anti-inflammatory or antioxidant activity, as they act in an antioxidant capacity in plants to defend against biotic and abiotic factors [35] . Antioxidant, antibacterial as well as anti-inflammatory activity has been attributed to Brazilin [36, 37] . Interestingly, in both traditional Chinese and Indian medicine, Brazilin has been used for skincare [36] . It has also been assessed for its anti-acne properties and was found to have sufficiently potent activity towards Propionibacterium acnes growth [38] . Brazilin has been shown to have anti-inflammatory capabilities which are of particular interest, as this study aims to develop a therapeutic for the treatment of inflammatory skin disorders [39, 40] . It may be that the observed anti-inflammatory abilities of Brazilin are in part be due to its inhibition of KLK5, although further investigation is required.
In recent years, several effective therapies and agents involving polyphenolic compounds have been introduced for inflammatory skin disorders such as AD treatment [30] . Polyphenolic compounds like tannic acid have demonstrated anti-inflammatory effects, a balance in Th1 and Th2 responses, suppression of angiogenesis, as well as decreased TNF-α-induced thymus-and activationregulated chemokine (TARC) expression in an AD mouse model [41] . Polyphenol compounds may be particularly effective treatments for inflammatory skin disorders because they are not only anti-inflammatory, but many of them, Brazilin included, also have antibacterial capabilities [42] . Patients with skin barrier dysfunction are often susceptible to bacterial and viral skin infections due to their disrupted skin barrier. Thus, treatment with a polyphenol compound could both reduce inflammation and prevent bacterial infection at the site of barrier defect.
Interestingly, Brazilin was also found to be an inhibitor of KLK14 (Table 2 ). KLK14 along with KLK5 are regarded as the major contributors to trypsin-like proteolytic activity in the skin [43] . It is thought that KLK14 can activate KLK5 (the proposed initiator to the KLK cascade in the skin) as part of a positive feedback response in vivo [3, 44] . As such, inhibition of KLK14 by Brazilin may lead to an additional reduction in KLK5 proteolytic activity through the loss of KLK14-mediated KLK5 activation in vivo. Brazilin also displayed some inhibitory effects towards KLK7 and KLK8 (Table 2 ). KLK7 is now thought to be the other major protease responsible for NS pathophysiology, with the removal of both KLK5 and KLK7 fully restoring epidermal barrier defect and postnatal fatality in LEKTIdeficient mice [45] . Therefore, the additional inhibition of KLK7 by Brazilin may contribute to restoration of the epidermal barrier and a further reduction in inflammation [28] . (A) KLK5 is represented by its Connolly surface color-coded by the calculated electrostatic potential. (B) Details of interaction between Brazilin and KLK5: three H-bonds (S1-pocket residue S195 and Q192 side chains, backbone carbonyl of S214), Brazilin's phenolic moiety binds in the S1 pocket of KLK5. The highly conserved, S1-pocket key residue D189, and three residues that constitute the proteolytic catalytic machinery are highlighted in orange (D102, H57 and S190). Only residues within 5 Å from the ligand are shown for clarity. H-bonds are depicted by dotted lines. Brazilin is shown in yellow.
in inflammatory disorders and warrants further investigation. Small natural plant-extracts called triterpenoids have also recently been observed to have inhibitory effects on KLK5, but these were found to be selective towards only the trypsin-like KLKs [46] .
A binding mode of interaction between Brazilin and KLK5 was hypothesized based on docking with Glide against the crystal structure of KLK5 (Figure 3) . Two phenolic groups of Brazilin form H-bonding interactions with S190 side chain in the S1-pocket and backbone carbonyl of S214, next to the S1'-pocket. The complex is stabilized by favorable van der Waals interaction and an additional H-bond between the aliphatic alcohol of Brazilin and Q192 side chain.
Mild-to-moderate skin inflammation may be adequately managed through the application of emollients and topical corticosteroids, but moderate-to-severe cases often require systemic immunosuppressants that have variable efficacy and safety concerns [47] . There is a pressing need for targeted therapies able to act both effectively and safely. Natural KLK5-specific small molecule inhibitors are ideal for topical skin disease drug design and remain a promising therapeutic for severe cases. In the future, optimized KLK inhibitors may have increased efficacy as therapeutics for inflammatory skin disorders without the broad immunosuppressive effects observed with the current steroid-based therapeutics [48, 49] .
